NEW DELHI — The Indian Pharmaceutical Association (IPA) has formally protested against the Recruitment Rules (RRs), 2026 for the Drugs Controller General of India (DCGI), arguing that new guidelines dangerously dilute technical expertise by opening the top regulatory role to candidates from non-pharmacy backgrounds, such as general sciences and engineering. The IPA asserts this move violates the Drugs and Cosmetics Act, 1940.
The IPA contends that the DCGI, as the Central Licensing Authority (CLA), requires specialized knowledge in pharmaceutical sciences and clinical pharmacology to ensure patient safety, making the inclusion of non-core backgrounds a risk to medicine quality. The association claims that the Drugs Inspector Welfare Association (DIWA) and other professionals demand the immediate withdrawal of these changes, arguing that the role demands specific, in-depth technical expertise in drug regulation rather than general administration.
Furthermore, the IPA and DIWA highlighted that global regulatory bodies, like the US FDA and the European Medicines Agency, rely on expert pharmaceutical professionals, suggesting that the new Indian rules could harm the country’s international reputation in the pharmaceutical sector. The IPA emphasized that safeguarding patient health requires the CDSCO to be led by those with specialized, hands-on experience, rejecting claims of a talent shortage.
The push to widen the candidate pool, noted by sources like Business Standard, followed difficulties in finding a permanent, eligible appointee. However, the pharma community, as noted in the IPA objection, is calling for a review of the rules to prioritize qualified professionals over administrative convenience, aiming to prevent a decline in drug safety standards.
